Skip to main content
Erschienen in: World Journal of Surgery 7/2004

01.07.2004 | Original Scientific Reports

Positive Status of α-Fetoprotein and des-γ-Carboxy Prothrombin: Important Prognostic Factor for Recurrent Hepatocellular Carcinoma

verfasst von: Masaki Kaibori, M.D., Yoichi Matsui, M.D., Hidesuke Yanagida, M.D., Norio Yokoigawa, M.D., A-Hon Kwon, M.D., Yasuo Kamiyama, M.D.

Erschienen in: World Journal of Surgery | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate prognostic factors after the recurrence of hepatocellular carcinoma (HCC) in patients who had undergone hepatic resection. We used univariate and multivariate retrospective analyses of 29 clinicopathologic factors in 143 patients with recurrent HCC. Patients were classified into four groups according to the positivity of tumor markers at the time of recurrence. Survival rates and prognostic factors were then compared among the four groups. Multivariate analysis revealed four independent prognostic factors at recurrence: albumin level < 3.5 g/dl (p = 0.0003), period until recurrence ≤ 1 year (p = 0.0004), positive status of α-fetoprotein and des-γ-carboxy prothrombin (AFP+/DCP+) (p < 0.0001), and portal vein invasion (p < 0.0001). Among groups with varying status of AFP/DCP, the survival rate in patients with AFP+/DCP+ at recurrence was significantly lower than those in the other three groups (+/+ 15.9% vs. +/- 47.2%, -/+ 44.8%, or -/- 61.1% at 3 years: p < 0.05). The AFP+/DCP+ group also had significantly higher rates of the recurrence appearing ≤ 1 year after operation (+/+ 68.3% vs. +/- 45.2%, -/+ 41.9%, or -/- 32.5%: p = 0.0108), extrahepatic recurrence (29.3% vs. 6.5%, 9.7%, or 5.0%: p = 0.0026), and no treatment at recurrence (29.3% vs. 9.7%, 9.7%, or 5.0%: p = 0.0115). These results indicate that the tumor markers AFP and DCP are significant prognostic factors for recurrent HCC, and their monitoring is essential for improving the prognosis after recurrence.
Literatur
1.
Zurück zum Zitat Fan, ST, Lo, CM, Liu, CL, et al. 1999Hepatectomy for hepatocellular carcinoma: toward zero hospital deathsAnn. Surg.229322330CrossRefPubMed Fan, ST, Lo, CM, Liu, CL,  et al. 1999Hepatectomy for hepatocellular carcinoma: toward zero hospital deathsAnn. Surg.229322330CrossRefPubMed
2.
Zurück zum Zitat Tung-Ping Poon, R, Fan, ST, Wong, J 2000Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinomaAnn. Surg.2321024CrossRefPubMed Tung-Ping Poon, R, Fan, ST, Wong, J 2000Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinomaAnn. Surg.2321024CrossRefPubMed
3.
Zurück zum Zitat Pompili, M, Rapaccini, GL, Luca, F, et al. 1997Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injectionCancer7915011508CrossRefPubMed Pompili, M, Rapaccini, GL, Luca, F,  et al. 1997Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injectionCancer7915011508CrossRefPubMed
4.
Zurück zum Zitat Poon, RT, Fan, ST, Ng, IO, et al. 2000Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinomaCancer89500507CrossRefPubMed Poon, RT, Fan, ST, Ng, IO,  et al. 2000Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinomaCancer89500507CrossRefPubMed
5.
Zurück zum Zitat Wayne, JD, Lauwers, GY, Ikai, I, et al. 2002Preoperative predictors of survival after resection of small hepatocellular carcinomasAnn. Surg.235722730CrossRefPubMed Wayne, JD, Lauwers, GY, Ikai, I,  et al. 2002Preoperative predictors of survival after resection of small hepatocellular carcinomasAnn. Surg.235722730CrossRefPubMed
6.
Zurück zum Zitat Ko, S, Kanehiro, H, Hisanaga, M, et al. 2002Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinomaBr. J. Surg.895762CrossRefPubMed Ko, S, Kanehiro, H, Hisanaga, M,  et al. 2002Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinomaBr. J. Surg.895762CrossRefPubMed
7.
Zurück zum Zitat Kubo, S, Hirohashi, K, Tanaka, H, et al. 2000Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinomaWorld J. Surg.2415591565CrossRefPubMed Kubo, S, Hirohashi, K, Tanaka, H,  et al. 2000Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinomaWorld J. Surg.2415591565CrossRefPubMed
8.
Zurück zum Zitat Koike, Y, Shiratori, Y, Sato, S, et al. 2000Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus: an analysis of 236 consecutive patients with a single lesionHepatology3212161223PubMed Koike, Y, Shiratori, Y, Sato, S,  et al. 2000Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus: an analysis of 236 consecutive patients with a single lesionHepatology3212161223PubMed
9.
Zurück zum Zitat Shimada, M, Takenaka, K, Gion, T, et al. 1996Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in JapanGastroenterology111720726PubMed Shimada, M, Takenaka, K, Gion, T,  et al. 1996Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in JapanGastroenterology111720726PubMed
10.
Zurück zum Zitat Hirohashi, K, Shuto, T, Kubo, S, et al. 2001Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virusJ. Hepatobiliary. Pancreat. Surg.88186CrossRefPubMed Hirohashi, K, Shuto, T, Kubo, S,  et al. 2001Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virusJ. Hepatobiliary. Pancreat. Surg.88186CrossRefPubMed
11.
Zurück zum Zitat Abelev, GI 1968Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical dataCancer Res.2813441350PubMed Abelev, GI 1968Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical dataCancer Res.2813441350PubMed
12.
Zurück zum Zitat Maringhini, A, Cottone, M, Sciarrino, E, et al. 1988Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosisDig. Dis. Sci.334751PubMed Maringhini, A, Cottone, M, Sciarrino, E,  et al. 1988Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosisDig. Dis. Sci.334751PubMed
13.
Zurück zum Zitat Weits, IC, Liebman, HA 1993Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical reviewHepatology18990997PubMed Weits, IC, Liebman, HA 1993Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical reviewHepatology18990997PubMed
14.
Zurück zum Zitat Kasahara, A, Hayashi, N, Fusamoto, H, et al. 1993Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizesDig. Dis. Sci.3821702176PubMed Kasahara, A, Hayashi, N, Fusamoto, H,  et al. 1993Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizesDig. Dis. Sci.3821702176PubMed
15.
Zurück zum Zitat Nakao, A, Suzuki, Y, Isshiki, K, et al. 1991Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseasesAm. J. Gastroenterol.866266PubMed Nakao, A, Suzuki, Y, Isshiki, K,  et al. 1991Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseasesAm. J. Gastroenterol.866266PubMed
16.
Zurück zum Zitat Nakao, A, Taniguchi, K, Inoue, S, et al. 1996Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinomaSemin. Surg. Oncol.12160163CrossRefPubMed Nakao, A, Taniguchi, K, Inoue, S,  et al. 1996Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinomaSemin. Surg. Oncol.12160163CrossRefPubMed
17.
Zurück zum Zitat Aoyagi, Y, Oguro, M, Yanagi, M, et al. 1996Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinomaCancer7717811786CrossRefPubMed Aoyagi, Y, Oguro, M, Yanagi, M,  et al. 1996Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinomaCancer7717811786CrossRefPubMed
18.
Zurück zum Zitat Sobin, LH, Wittekind, C 1997TNM classification of malignant tumours5th editionWileyNew York Sobin, LH, Wittekind, C 1997TNM classification of malignant tumours5th editionWileyNew York
19.
Zurück zum Zitat Tung-Ping-Poon, R, Fan, ST, Oi-Lin Ng, I 2000et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisalAnn. Surg.231544551CrossRefPubMed Tung-Ping-Poon, R, Fan, ST, Oi-Lin Ng, I 2000et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisalAnn. Surg.231544551CrossRefPubMed
20.
Zurück zum Zitat Shimada, M, Takenaka, K, Fujiwara, Y, et al. 1996Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinomaCancer7820942100CrossRefPubMed Shimada, M, Takenaka, K, Fujiwara, Y,  et al. 1996Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinomaCancer7820942100CrossRefPubMed
21.
Zurück zum Zitat Degos, F, Christidis, C, Ganne-Carrie, N, et al. 2000Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and deathGut47131136CrossRefPubMed Degos, F, Christidis, C, Ganne-Carrie, N,  et al. 2000Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and deathGut47131136CrossRefPubMed
22.
Zurück zum Zitat Khan, MH, Farrell, GC, Byth, K, et al. 2000Which patients with hepatitis C develop liver complications?Hepatology31513520CrossRefPubMed Khan, MH, Farrell, GC, Byth, K,  et al. 2000Which patients with hepatitis C develop liver complications?Hepatology31513520CrossRefPubMed
23.
Zurück zum Zitat Hu, KQ, Tong, MJ 1999The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United StatesHepatology2913111316CrossRefPubMed Hu, KQ, Tong, MJ 1999The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United StatesHepatology2913111316CrossRefPubMed
24.
Zurück zum Zitat Koike, Y, Shiratori, Y, Sato, S, et al. 2001Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinomaCancer91561569CrossRefPubMed Koike, Y, Shiratori, Y, Sato, S,  et al. 2001Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinomaCancer91561569CrossRefPubMed
25.
Zurück zum Zitat Hamamura, K, Shiratori, Y, Shiina, S, et al. 2000Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum à-fetoproteinCancer8815571564CrossRefPubMed Hamamura, K, Shiratori, Y, Shiina, S,  et al. 2000Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum à-fetoproteinCancer8815571564CrossRefPubMed
Metadaten
Titel
Positive Status of α-Fetoprotein and des-γ-Carboxy Prothrombin: Important Prognostic Factor for Recurrent Hepatocellular Carcinoma
verfasst von
Masaki Kaibori, M.D.
Yoichi Matsui, M.D.
Hidesuke Yanagida, M.D.
Norio Yokoigawa, M.D.
A-Hon Kwon, M.D.
Yasuo Kamiyama, M.D.
Publikationsdatum
01.07.2004
Erschienen in
World Journal of Surgery / Ausgabe 7/2004
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-004-7205-y

Weitere Artikel der Ausgabe 7/2004

World Journal of Surgery 7/2004 Zur Ausgabe

Letters to the Editor

To the Editor

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.